Phase IV trial results show Eylea dosing schedule improvement is possible

Bayer’s recently released results from the trial have shown that there can be greater flexibility in the treatment regimen for patients with macular degeneration using Eylea. Credit: Image Point Fr / Shutterstock.



  • Eylea macular degeneration